GLP-1 Lawsuit Claim Review: Questions to Ask an Attorney

Ask an attorney whether your exact drug, injury, medical evidence, timing, and filing deadline support an individual GLP-1 lawsuit. Also ask how other health conditions, prior warnings, and the multidistrict litigation process could affect your claim. GLP-1 receptor agonists are medicines involved in product-liability allegations concerning serious gastrointestinal injuries. Multidistrict litigation, or an MDL, coordinates related federal cases for pretrial proceedings without turning them into one class action.

Table of Contents

• Does my drug and injury fit the litigation?
• What records establish the diagnosis and timing?
• What other explanations could affect causation?
• Which warning label applies to my use?
• Is this an individual case or a class payout?
• What can adverse-event reports actually prove?

Does my drug and injury fit the litigation?

Federal MDL No. 3094 coordinates personal-injury claims involving Ozempic, Wegovy, Rybelsus, Trulicity, and Mounjaro. The alleged injuries include gastroparesis, ileus, intestinal obstruction or pseudo-obstruction, and other gastrointestinal conditions. Ask the attorney to identify the manufacturer, reason for treatment, dose history, dates of use, and precise diagnosis. Taking a listed medicine does not by itself establish a claim.

The Eastern District of Pennsylvania's MDL page says plaintiffs allege inadequate warnings and misleading safety representations; Novo Nordisk and Eli Lilly deny the allegations. Vision-loss allegations require a separate review. The U.S. Judicial Panel on Multidistrict Litigation created MDL No. 3163 for claims that specified GLP-1 drugs caused non-arteritic anterior ischemic optic neuropathy, or NAION, and kept those proceedings separate from the gastrointestinal MDL.

What records establish the diagnosis and timing?

Ask which records show when treatment began, when symptoms appeared, and when a clinician diagnosed the injury. A useful chronology should include prescriptions, dose changes, prescribers, pharmacies, emergency visits, hospitalizations, tests, treatment, and any discontinuation of the medicine. The MDL's Plaintiff Fact Sheet order requires medication dates, prescribers, pharmacies, treatment, and hospitalization information.

A claimant alleging gastroparesis must also provide medical records containing confirmatory diagnostic testing. Ask the attorney to identify missing evidence before filing. Useful questions include:.

• Does the medical record name the claimed injury, or only describe symptoms?
• Is the relevant diagnostic test available?
• Do prescription and pharmacy records confirm exposure dates?
• Are hospital and specialist records complete?
• Does the timeline show symptoms before, during, or after treatment?

What other explanations could affect causation?

Ask how diabetes, earlier gastrointestinal problems, other medicines, surgeries, and medical procedures could affect the causation analysis. These factors do not automatically defeat a claim, but the attorney should explain how the records distinguish the alleged drug-related injury from other possible causes. The MDL fact sheet requires information about prior conditions, treatment history, health-care providers, and medications used from five years before GLP-1 treatment onward.

Give counsel a complete history rather than selecting only favorable records. Ask what evidence creates difficulties as well as what supports the case. The answer should address preexisting symptoms, alternative diagnoses, treatment gaps, and whether the claimed condition improved or continued after the medication stopped.

Which warning label applies to my use?

Ask counsel to compare the warning available when you used the medicine with later label language. A later warning may help frame the issue, but it does not establish what the manufacturer disclosed during an earlier treatment period. For example, the FDA's Ozempic prescribing information revised in January 2025 states that severe gastrointestinal reactions occurred more often with Ozempic than placebo in trials.

It also says Ozempic is not recommended for patients with severe gastroparesis. The attorney should identify the label version tied to each prescription period. Ask what the prescriber knew, what warning was available, and how those facts relate to the specific legal theory.

Is this an individual case or a class payout?

Do not assume the MDL creates automatic eligibility, shared compensation, or a class settlement. Ask where an individual complaint would be filed, which deadline applies, and what facts determine whether counsel would accept the case. Under Case Management Order No.

27, the MDL master complaint does not merge individual claims. Each member case must have its own complaint. Before signing an agreement, ask who will handle the case, how often the firm provides updates, what fee applies, and who pays case expenses if the claim does not succeed. Also ask whether the firm expects individual review, coordinated settlement discussions, or another strategy.

What can adverse-event reports actually prove?

Ask whether the attorney relies on medical records, diagnostic testing, label evidence, or adverse-event reports. These sources do different jobs and should not be treated as interchangeable.

The FDA says adverse-event reports can support a safety investigation, but they cannot alone prove that a medicine caused a particular injury or establish how often it occurs. Reviewers need additional information and multiple evidence sources to assess causation. Bring counsel the drug packaging or prescription details, a medication timeline, diagnostic records, hospital records, and a complete list of prior conditions and medicines.

You Might Also Like

• Camp Lejeune Lawsuit Mistakes: Deadlines and Documents Claimants Miss
• Toxic Exposure Lawsuit FAQ: Rights, Deadlines, and Legal Process
• Talc Lawsuit Settlement Timeline: Filing, Discovery, Settlement, and Trial

Browse more: Arbitration | Attorneys | Claims | Compensation | Consumer